Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone and Doxycycline in Seropositive Chronic Lyme Disease
NCT00001101Phase 3
Key facts
- Status
- Completed
- Primary completion
- Mar 2001
- Countries
- 1
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Reversible Covalent Inhibitors
- Conditions
- Lyme disease
01
Overview
Phase 3, randomised, double-blind trial of ceftriaxone and doxycycline in Lyme disease (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Antibiotic therapy
Ceftriaxone IV for 30 days followed by doxycycline orally for 60 days
Placebo
Placebo IV for 30 days followed by placebo orally for 60 days
03
Who it enrols
Adults with seropositive chronic Lyme disease, documented history of acute Lyme disease and prior antibiotic treatment, with symptoms persisting for 6 months to 12 years.
Beyond the preview
Go deeper on NCT00001101.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001101.